-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s upright polypropylene infusion bag–packaged moxifloxacin hydrochloride and sodium chloride injection has been approved.
Category:
发布时间：2025-05-09
【概要描述】
On May 8, the upright polypropylene infusion bag–packaged moxifloxacin hydrochloride and sodium chloride injection (250 mL), developed by Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration, further facilitating clinical use and expanding therapeutic options.
On May 8, the upright polypropylene infusion bag–packaged moxifloxacin hydrochloride and sodium chloride injection (250 mL), developed by Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration, further facilitating clinical use and expanding therapeutic options.
According to reports, moxifloxacin hydrochloride and sodium chloride injection is indicated for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated skin and soft-tissue infections, complicated skin and soft-tissue infections, complicated intra-abdominal infections, and plague—conditions caused by susceptible bacteria in adults (≥18 years of age).
According to data from MeneNet, moxifloxacin hydrochloride sodium chloride injection is a product with annual sales exceeding RMB 1 billion. Over the past two years, its market size across the three major distribution channels—urban public hospitals, county-level public hospitals, and township health centers—has approached RMB 2 billion, with sales reaching approximately RMB 1.416 billion in 2022, about RMB 1.885 billion in 2023, and roughly RMB 1.892 billion in 2024.
In recent years, the Group has adhered to a strategy that combines generic development with innovative R&D, continuously strengthening innovation-driven empowerment and accelerating the integrated development of “active pharmaceutical ingredients plus finished dosage forms.” The moxifloxacin hydrochloride product portfolio has gradually taken shape, with approved products including moxifloxacin hydrochloride sodium chloride injection, moxifloxacin hydrochloride ophthalmic solution, moxifloxacin hydrochloride tablets, and the corresponding API. This ongoing expansion of the product matrix underscores the Group’s growing resilience and sustained growth momentum.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091